NCT04398173

Brief Summary

To assess prostate cancer (PCa) detection rate in men undergoing magnetic resonance imaging (MRI) before planning prostate biopsy. Results will be stratified considering men with/without previous negative prostate biopsy. Secondary objective will be to compute the negative predictive value of MRI in subject with no lesion detected at imaging or no cancer confirmed at biopsy, considering a follow-up of at least 2 years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2014

Completed
5.2 years until next milestone

First Submitted

Initial submission to the registry

January 30, 2020

Completed
4 months until next milestone

First Posted

Study publicly available on registry

May 21, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

April 14, 2021

Status Verified

April 1, 2021

Enrollment Period

6 years

First QC Date

January 30, 2020

Last Update Submit

April 13, 2021

Conditions

Keywords

magnetic resonance imagingprostate biopsy

Outcome Measures

Primary Outcomes (1)

  • PCa detection rate

    Number of men with positive prostate biopsy over the number of men with a positive MRI

    24 months

Secondary Outcomes (1)

  • Negative predictive value of MRI

    24 months

Study Arms (2)

Group A (previous negative biopsy)

Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI

Diagnostic Test: multiparametric MRI

Group B (biopsy naive)

Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI

Diagnostic Test: multiparametric MRI

Interventions

multiparametric MRIDIAGNOSTIC_TEST

T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging

Group A (previous negative biopsy)Group B (biopsy naive)

Eligibility Criteria

Age50 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Men with clinical suspicion of PCa, eligible for prostate biopsy

You may qualify if:

  • age 50 and life expectancy greater than 10 years
  • PSA values persistently greater than 4 ng/ml
  • multiparametric MRI of the prostate between nov-2014 and nov-2016
  • MRI with endorectal coil

You may not qualify if:

  • previous history of PCa

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute

Candiolo, Turin, 10060, Italy

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Multiparametric Magnetic Resonance Imaging

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Magnetic Resonance ImagingTomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 30, 2020

First Posted

May 21, 2020

Study Start

November 1, 2014

Primary Completion

October 31, 2020

Study Completion

December 31, 2020

Last Updated

April 14, 2021

Record last verified: 2021-04

Locations